GI
IMVT icon

GAMMA Investing’s Immunovant IMVT Stock Holding History

GAMMA Investing’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$41.3K Buy
1,224
+476
+64% +$18.8K ﹤0.01% 2497
2026
Q2 		$28.8K Buy
748
+44
+6% +$1.34K ﹤0.01% 2641
2026
Q1 		$17.5K Buy
704
+192
+38% +$4.97K ﹤0.01% 2783
2025
Q4 		$13K Buy
512
+162
+46% +$3.61K ﹤0.01% 2850
2025
Q3 		$5.64K Buy
350
+48
+16% +$777 ﹤0.01% 3130
2025
Q2 		$4.83K Sell
302
-12
-4% -$181 ﹤0.01% 3136
2025
Q1 		$5.37K Buy
314
+177
+129% +$3.7K ﹤0.01% 3059
2024
Q4 		$3.39K Buy
137
+45
+49% +$1.28K ﹤0.01% 3056
2024
Q3 		$2.62K Buy
92
+14
+18% +$413 ﹤0.01% 2980
2024
Q2 		$2.06K Sell
78
-32
-29% -$910 ﹤0.01% 2876
2024
Q1 		$3.55K Buy
110
+31
+39% +$1.13K ﹤0.01% 2542
2023
Q4 		$2.88K Buy
+79
New +$2.91K ﹤0.01% 2461

Other funds holding IMVT

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

GAMMA Investing's IMVT Position: Q3 2026 in Review

GAMMA Investing increased its Immunovant (IMVT) stake by 64% in Q3 2026, buying an estimated $18.8K and bringing the position to 1,224 shares worth $41.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2497.

GAMMA Investing first reported a position in IMVT in Q4 2023 and has held it in 12 quarters since. 5 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • GAMMA Investing held 1,224 shares of Immunovant worth $41.3K as of Q3 2026.
  • GAMMA Investing bought 476 Immunovant shares in Q3 2026, an estimated $18.8K.
  • Immunovant made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2497 holding.
  • GAMMA Investing first reported a position in Immunovant in Q4 2023 and has held it in 12 quarters since.
  • 5 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.